Literature DB >> 23765422

Hypoxia-dependent mRNA expression pattern of splicing factor YT521 and its impact on oncological important target gene expression.

Marc Hirschfeld1, Bo Zhang, Markus Jaeger, Stefan Stamm, Thalia Erbes, Sebastian Mayer, Xiaowen Tong, Elmar Stickeler.   

Abstract

The ubiquitously expressed splicing factor YT521 (YTHDC1) is characterized by alternatively spliced isoforms with regulatory impact on cancer-associated gene expression. Our recent findings account for the prognostic significance of YT521 in endometrial cancer. In this study, we investigated the hypoxia-dependency of YT521 expression as well as its differential isoform activities on oncological important target genes. YT521's potential regulatory influence on splicing was investigated by a minigene assay for the specific target gene CD44. Functional splicing analysis was performed by YT521 knock-down or overexpression, respectively. In addition, YT521 expression was determined under hypoxia. The two protein-generating YT521 mRNA isoforms 1 and 2 caused a comparable, specific induction of CD44v alternative splicing (P < 0.01). In a number of oncological target genes, YT521 upregulation significantly altered BRCA2 expression pattern, while YT521 knock-down created a significant regulatory impact on PGR expression, respectively. Hypoxia induced a specific switch towards the processing of two non-protein-coding mRNA variants, of which one is described for the first time in this study. The presented study underlines the comparable regulatory potential of both YT521 isoforms 1 and 2, on the investigated target genes in vivo and in vitro. Hypoxia induces a specific switch in YT521 expression pattern towards the two non-protein coding mRNA variants, the already characterized isoform 3 and the newly discovered exon 8-skipping isoform. The altered YT521 alternative splicing is functionally coupled with nonsense-mediated decay and can be interpreted as regulated unproductive splicing and transcription with consecutive impact on the processing of specific cancer-associated genes, such as BRCA2 and PGR.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRCA2; YT521; cancer; hypoxia; splicing

Mesh:

Substances:

Year:  2013        PMID: 23765422     DOI: 10.1002/mc.22045

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  17 in total

Review 1.  Small changes, big implications: The impact of m6A RNA methylation on gene expression in pluripotency and development.

Authors:  Adam M Heck; Carol J Wilusz
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2019-07-17       Impact factor: 4.490

Review 2.  N6-methyladenine RNA modification and cancers.

Authors:  Xia Wu; Lina Sang; Yuping Gong
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

3.  YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A.

Authors:  Bo Zhang; Xiaowen Shao; Jianhong Zhou; Jin Qiu; Yi Wu; Jiajing Cheng
Journal:  Tumour Biol       Date:  2015-08-21

4.  Constitutive patterns of gene expression regulated by RNA-binding proteins.

Authors:  Davide Cirillo; Domenica Marchese; Federico Agostini; Carmen Maria Livi; Teresa Botta-Orfila; Gian Gaetano Tartaglia
Journal:  Genome Biol       Date:  2014-01-02       Impact factor: 13.583

Review 5.  Alternative RNA structure-coupled gene regulations in tumorigenesis.

Authors:  Feng-Chi Chen
Journal:  Int J Mol Sci       Date:  2014-12-29       Impact factor: 5.923

Review 6.  The RNA Modification N6-methyladenosine and Its Implications in Human Disease.

Authors:  Pedro J Batista
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-05-19       Impact factor: 7.691

Review 7.  Dynamic transcriptomic m6A decoration: writers, erasers, readers and functions in RNA metabolism.

Authors:  Ying Yang; Phillip J Hsu; Yu-Sheng Chen; Yun-Gui Yang
Journal:  Cell Res       Date:  2018-05-22       Impact factor: 25.617

8.  The Oncogene Metadherin Interacts with the Known Splicing Proteins YTHDC1, Sam68 and T-STAR and Plays a Novel Role in Alternative mRNA Splicing.

Authors:  Hayley J Luxton; Benjamin S Simpson; Ian G Mills; Nicola R Brindle; Zeba Ahmed; Vasilis Stavrinides; Susan Heavey; Stefan Stamm; Hayley C Whitaker
Journal:  Cancers (Basel)       Date:  2019-08-23       Impact factor: 6.639

Review 9.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15

Review 10.  Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.

Authors:  Serena Bonomi; Stefania Gallo; Morena Catillo; Daniela Pignataro; Giuseppe Biamonti; Claudia Ghigna
Journal:  Int J Cell Biol       Date:  2013-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.